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Microvesicles (MVs) are submicron vesicles with sizes of 0.1–1.0  μm in diameter, 
released from various cell types upon activation or apoptosis. Their involvement in a 
variety of diseases has been intensively investigated. In blood, platelets are potent MV 
secretors, and oxidized low-density lipoprotein (oxLDL), a platelet ligand, induces plate-
let activation and thus potentially MV secretion. This interaction occurs through binding 
of oxLDL with CD36, located on the platelet membrane. In this study, we investigated 
the effect of in vitro incubation of platelets with oxLDL on MV release. Furthermore, we 
compared the results obtained when separating MVs larger than 0.5 μm as a measure 
of results obtained from less sensitive conventional flow cytometers with MVs below the 
0.5 μm limit. MV size distribution was analyzed in plasma from 11 healthy volunteers (four 
females and seven males). MVs were identified as <1 μm and positive for lactadherin 
binding and cell-specific markers. Platelet-rich plasma (PRP) was incubated without and 
with oxLDL or LDL (as control) to investigate the impact on platelet activation, evident by 
release of MVs. Size-calibrated fluorescent beads were used to establish the MV gate, 
and separate small- and large-size vesicles. CD41+ and CD41+CD36+ MVs increased by 
six to eightfold in PRP, when left at room temperature, and the presence of cell-specific 
markers increased. Total MV count was unaffected. Incubations with oxLDL did not 
increase the MV release or affect the distribution of small- and large-size MVs. We found 
a large interindividual variation in the fraction of small- and large-size MVs of 73%. In 
conclusion, we propose that procoagulant activity and activation of platelets induced by 
interaction of platelet CD36 with oxLDL may not involve release of MVs. Furthermore, our 
results demonstrate great interindividual variability in size distribution of platelet-derived 
MVs and thereby stress the importance for generation of standardized protocols for MV 
quantification by flow cytometry.
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FigUre 1 | The centrifugation procedure.
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inTrODUcTiOn
Microvesicles (MVs) are submicron vesicles with sizes of 
0.1–1.0  μm in diameter. They are released from various cell 
types as a result of cellular activation or apoptosis (1). In recent 
years, MVs have received more attention due to their poten-
tial involvement in a variety of disease states, such as cancer, 
inflammatory and autoimmune diseases, cardiovascular disor-
ders, and the metabolic syndrome (2–6). The roles of MVs are 
diverse. They have been shown to transfer material, in the form 
of membrane proteins, DNA, RNA, receptors, or cytoplasmic 
components, from the parent cell to recipient cells in other areas 
of the body (1).
Platelets are potent MV secretors in blood. Various ligands 
potentiate platelet activation, which can lead to MV secretion.
Oxidized low-density lipoprotein (oxLDL) known to induce 
a prothrombotic state activates platelets through binding with 
CD36 (7, 8), a scavenger receptor abundantly present in the 
platelet membrane. Studies have shown that when platelet CD36 
binds oxLDL, specific intracellular signaling cascades are acti-
vated, resulting in platelet activation (9, 10), thus promoting a 
prothrombotic state and possibly the release of MVs.
Flow cytometry is a widely used method for the detection of 
MVs originating from different cells or tissues. The method is 
a powerful tool to detect, quantify, and characterize MVs, but 
the sensitivity of most instruments is challenged by the small 
size of the particles and the entailing dim signal. Several studies, 
performed on conventional flow cytometers, report a detection 
limit of 0.5 μm (11), which possibly discards a vast amount of 
the MVs as background noise or debris. The more dedicated flow 
cytometers allows for detection below 0.5 μm thereby providing 
access to the small-size MVs (12). The relationship between 
MVs measured by conventional flow cytometers and the results 
obtained when measuring within the full MV size range may be 
important for the interpretation and comparison of new data with 
older, obtained by less sensitive flow cytometers.
The primary aim of this study was to investigate the impact 
of in  vitro incubation of platelets with oxLDL on secretion of 
platelet-derived MVs (PMVs) and in particular PMVs carrying 
CD36 measured by a sensitive flow cytometer. The secondary aim 
was to compare the results obtained when separating MVs larger 
than 0.5 μm as a measure of results obtained from less sensitive 
conventional flow cytometers with MVs below the 0.5 μm limit.
MaTerials anD MeThODs
Donors and Blood collection
Eleven healthy volunteers were included in the study (four 
females and seven males). According to a medical questionnaire, 
the participants were free of any overt disease, non-smoking and 
had not been taking any medication affecting coagulation for the 
past 10  days. Blood samples were drawn from the antecubital 
vein with the help of a tourniquet and using a butterfly system 
with a 21-G needle (SAFETY blood collection set, 21 G, Vacuette, 
Greiner Bio-one, Kremsmünster, Austria). Blood was collected 
into 3.2% (0.109M) citrated tubes (Vacuette®, 9  mL, Greiner 
Bio-one, Kremsmünster, Austria), K3E EDTA tubes, and Lithium 
Heparin (Vacuette®, 3  mL, Greiner Bio-one, Kremsmünster, 
Austria). Biochemical screening was performed on a Cobas® 
6000 analyzer (Roche Diagnostics Ltd., Switzerland) and an 
Advia 2120i Hematology Systems (Siemens, Germany). A 
Sysmex KX-21N Automated Hematology Analyzer (Sysmex 
Corporation, Japan) was also used for measuring platelet 
count in platelet-rich plasma (PRP). The study was conducted 
in agreement with the Declaration of Helsinki, and the protocol 
was approved by the local Ethics Committee of North Region 
Denmark (Reg. Nb. N-20110067). Informed written consent 
was obtained from all study participants.
sample Preparation
Citrated blood samples were centrifuged at two different set-
tings to obtain both PRP and platelet-free plasma (PFP). The 
latter was used as control in the experimental set-up. To obtain 
PRP, the blood samples were centrifuged at 2000 g for 4 min at 
20°C, and to obtain PFP, the samples were centrifuged at 2000 g 
for 25  min at 20°C. Autologous PFP was used for adjusting 
platelet count in PRP to contain 150–200 × 10−9/L. Before flow 
cytometry analyses, all plasma samples were further centrifuged 
at 3000 g for 10 min in order to remove platelets. Since much 
smaller volumes were centrifuged following incubations. Stoke’s 
equation was used for calculation of g-force and time to obtain 
sedimentation distance comparable to that used for generation 
of PPP. A flow chart describing the centrifugation procedure is 
presented in Figure 1.
TaBle 1 | characterization of the study population (n = 11).
Male (n = 7) Female (n = 4)
Age (years) 40.86 ± 12.92 45.25 ± 8.73
BMI (kg/m2) 24.04 ± 3.06 23.89 ± 2.42
Hemoglobin (mmol/L) 9.24 ± 0.46 8.65 ± 0.69
Platelet count (109/L) 263 ± 41.95 281.75 ± 77.94
Leukocyte count (109/L) 5.17 ± 0.76 7.08 ± 2.16
Glucose (mmol/L) 4.83 ± 0.43 4.28 ± 0.69
ALT (U/L) 21.57 ± 5.65 14 ± 6.98
Total-C (mmol/L) 4.91 ± 1.18 4.73 ± 0.79
HDL-C (mmol/L) 1.33 ± 0.20 1.50 ± 0.27
LDL-C (mmol/L) 3.11 ± 1.11 2.80 ± 0.67
Triglycerides (mmol/L) 1.10 ± 0.12 0.93 ± 0.26
Values are shown as mean ± SD. Abbreviations: BMI, body mass index; ALT, alanine 
aminotransferase; Total-C, total cholesterol; HDL-C, HDL cholesterol; LDL-C, LDL 
cholesterol.
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incubation of PrP with native lDl or oxlDl
The fresh PRP samples were incubated without or with either 
oxLDL or native LDL (oxLDL, 2  mg/mL, cat# BT-910; nLDL, 
5 mg/mL, cat# BT-903, Biomedical Technologies Inc., MA, USA) at 
increasing concentrations: 0-, 10-, 20-, and 40 μg/mL for 30 min at 
room temperature (RT). The oxLDL was generated by copper sul-
fate oxidation of LDL. The lot used in this study migrated 2.1-fold 
further than LDL on an agarose gel, and it was used for experiments 
within 4 weeks. The lowest concentration of 10 μg/mL corresponds 
to physiological levels found in individuals without metabolic syn-
drome (13). Plasma samples were further centrifuged, as described 
in Figure 1, and stored at −80°C until MV analysis.
MV labeling
Fifty microliters of freshly thawed plasma were transferred to a 
TruCount™ tube (BD Bioscience, NJ, USA) containing a lyophi-
lized pellet, releasing a known number of fluorescent beads. MVs 
were then labeled with 5 μL fluorescein isothiocyanate (FITC)-
conjugated lactadherin (83 μg/mL, Hematologic Technologies Inc., 
VT, USA). Lactadherin is a specific marker of MVs due to its bind-
ing to phosphatidyl-serin (PS) exposed on the surface of MVs (12). 
To identify MVs originating from platelets and whether or not they 
express CD36, MVs were further labeled with 3 μL allophycocyanin 
(APC)-conjugated antihuman CD41 (25  μg/mL IgG1, κ, clone 
HIP8, BioLegend, San Diego, CA, USA) and 3 μL phycoerythrin 
(PE)-conjugated antihuman CD36 (25 μg/mL IgG2a, κ, clone 5-27, 
BioLegend, San Diego, CA, USA). Isotype controls matching each 
antibody were used as negative controls, APC-conjugated mouse 
IgG1 κ (clone MOPC-21, BioLegend, San Diego, CA, USA) and 
PE-conjugated mouse IgG2a κ (clone MOPC-173, BioLegend, San 
Diego, CA, USA). After 30 min incubation time (4°C in the dark), 
200 μL 0.22 μm filtered PBS was added to each labeled sample.
Flow cytometry
After incubation with antibodies and addition of PBS, the samples 
were immediately analyzed using BD FACSAria™ III High Speed 
Cell Sorter, which incorporates three air-cooled lasers at 375, 488, 
and 633 nm wavelengths and is equipped with BD FACSDiva™ 
software (v.6.1.3). The procedure was essentially as described in 
Ref. (12) except that no neutral density filter was used. The sam-
ples were analyzed at a max rate of 20000 events per second and 
when MV counts reached 500000 events (in two cases 1000000) 
within the MV gate, the analysis was stopped.
To establish a MV gate, preliminary standardization experi-
ments were conducted using a blend of size-calibrated fluorescent 
beads with a size range of 0.2 (Invitrogen) to 3.0 μm [Megamix 
beads (0.5, 0.9, and 3.0 μm), Biocytex, Marseille, France]. The 
upper and outer limits of the MV gate were established just 
above the size distribution of the 0.9 μm beads, and the lower 
limit was set to include the 0.2 μm beads to obtain a MV gate of 
approximately 0.1–1 μm in a forward (FSC-H) and side scatter 
(SSC-H) setting (log scale) (Figure  2A) using the “auto-gate” 
function inside the Flow Jo™ software (v.8.8.7, Tree Star Inc., 
OR, USA). We defined MVs as particles within the MV gate, 
which had positive staining for lactadherin (PS+), and expressed 
cell-specific markers.
For MV quantification, TruCount™ beads (4.2  μm in 
diameter) with a known number of fluorescent beads were used 
according to the manufacturer’s manual. The following formula 
was used to calculate the number of MV events per microliter: 
(number of events in the MV region ×  number of beads per 
test)/(number of events in the absolute count bead region × test 
volume). The number of beads in TruCount™ tubes was pro-
vided by the manufacturer, and the test volume was 50 μL. PBS 
(0.22 μm filtered) was analyzed under conditions identical to the 
MV samples in order to obtain information of background noise.
To determine the fraction of small- and large-size MVs and 
investigate whether oxLDL affects the size distribution of MV 
release following incubation, two gates were established on the 
basis of the original MV gate. By using the 0.5 μm beads as the 
upper and lower limits of two new gates, we obtained a small-size 
gate ranging from the lower border of the 0.2 μm beads to the 
0.5 μm beads and a large-size gate from 0.5 μm to the upper bor-
der of the 0.9 μm beads, in a FSC-H and SSC-H setting (Figure 2).
Mean fluorescence intensity (MFI) refers to the fluorescence 
intensity of each event in average and is, in our case, calculated 
using the geometric mean, which weights high and low values 
equally, and is applied when normal distribution is absent.
statistical analysis
Statistical analyses were performed using SPSS Version 22 (SPSS 
Inc., IBM Corporation, NY, USA). MV data were expressed as 
median (interquartile range) and not normally distributed as 
evident by the Shapiro–Wilk test for normality. For analysis of 
two related samples, the Wilcoxon signed rank test was used, 
and for analysis of variance, the Friedman test was used. P values 
≤0.05 indicated a statistically significant difference. For box plot, 
outliers were defined as cases that fall more than 1.5 times the box 
length from either end of the box.
resUlTs
study Participants
The study population consisted of healthy, lean males and females 
between 28 and 60 years of age. Characteristics of the study par-
ticipants are given in Table 1.
TaBle 3 | analysis of variance for oxlDl and control incubations.
oxlDl control
MV cOUnT
CD41+ MV counts 0.427 0.301
CD41+CD36+ MV counts 0.792 0.409
MFi
Lactadherin 0.465 0.525
CD41 0.591 0.591
CD36 0.288 0.167
P values for MV counts and MFI, determined by the Friedman test.
FigUre 2 | construction of MV gates using size-calibrated fluorescent beads. (a) Selection of bead subsets using FACSAria instrument with a set SSC-H 
threshold of 200, and determination of small- (<0.5 μm) and large-size (>0.5 μm) gates. The solid square is the total MV gate and the dotted line separates the 
small- and the large-size gates. (B) Application of the MV gates to a plasma sample.
TaBle 2 | MV counts within the MV gate.
cD41+ cD41+cD36+
oxlDl
10 μg/mL 1129 (505–2837) 938 (260–1509)
20 μg/mL 1044 (565–2396) 867 (497–1471)
40 μg/mL 762 (620–2694) 695 (407–1695)
nlDl
0 μg/mL 1374 (690–2499) 819 (427–1552)
10 μg/mL 699 (426–2084) 506 (240–1273)
20 μg/mL 1173 (696–2162) 819 (539–1433)
40 μg/mL 789 (533–3597) 710 (405–1878)
Values are shown as counts per microliter plasma and expressed as median 
(interquartile range).
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The MV Profile of PrP and PFP after 
incubation
To investigate the MV release from platelets when left for 30 min 
at RT, we compared MV counts and MFI values of PRP and PFP. 
The latter represent the MV profile at the time of blood collection.
The CD41+ MV counts increased sixfold after 30  min at 
RT [200 (121–498) vs. 1374 (690–2499) counts per microliter 
plasma, P < 0.005]. Likewise, CD41+CD36+ MV counts increased 
eightfold [99 (79–239) vs. 819 (427–1552) counts per microliter 
plasma, P < 0.005]. No change in total MV counts was observed 
(Figure 3A). MFI values, representing the mean density of the 
antigen, were significantly higher in PRP compared with PFP, 
for lactadherin binding [585 (383–1028) vs. 941 (508–1410) 
counts per microliter plasma, P < 0.005] as well as CD41 [925 
(608–1371) vs. 1303 (826–1824) counts per microliter plasma, 
P <  0.005] and CD36 [1089 (984–2139) vs. 1617 (1184–2811) 
counts per microliter plasma, P < 0.005] (Figure 3B).
PMV release after oxlDl incubation
Platelet-rich plasma was incubated with oxLDL or nLDL as con-
trol in order to investigate the effect on platelet release of MVs, 
particularly platelet-derived CD36+ MVs. Table 2 shows CD41+ 
MV counts and CD41+CD36+ MV counts after incubation with 
oxLDL and control. To investigate whether incubations with 
oxLDL had any effect on the density of investigated MV labels, 
the MFI values of lactadherin binding, CD41, and CD36 were 
calculated within the MV gate.
As shown in Table 3, the analysis of variance test showed no 
significant effect of any of the incubations for neither CD41+ nor 
CD41+CD36+ MV counts nor MFI values.
The Fraction of small- Vs. large-size PMVs
The fraction of small- vs. large-size PMVs was not affected 
when plasma was left for 30 min at RT [0.32 (0.18–0.50) vs. 0.29 
(0.15–0.35), P = 0.113]. Figure 4 shows flow cytometric data of 
total PMV counts, small- and large-size PMV counts, as well as the 
isotype control, which show no unspecific binding. The intra- and 
interindividual differences between small- and large-size PMVs 
were explored using the described gating strategy. The fraction of 
small- and large-size PMVs was not significantly affected during 
incubation with oxLDL or nLDL, whereas the interindividual 
variation was 73% (Figure 5).
FigUre 3 | MV release from PrP at room temperature. Effect of incubation of PRP for 30 min at room temperature on MV counts (a) and MFI values (B) on 
MVs within the MV gate (total PS+ MVs) expressing CD41 (PS+CD41+ MVs) and CD36 (PS+CD41+CD36+ MVs) compared to MVs in PFP. Values are shown as 
counts per microliter plasma and expressed as median (interquartile range). *P < 0.005, Wilcoxon signed rank test. Circles represent outliers.
November 2015 | Volume 2 | Article 375
Nielsen et al. oxLDL and MV Release from Platelets
Frontiers in Cardiovascular Medicine | www.frontiersin.org
DiscUssiOn
In this study, we investigated the MV profile after in  vitro 
incubation of platelets with oxLDL, an interaction hypothesized 
to occur through the scavenger receptor CD36 located on the 
platelet surface. Furthermore, we compared the fraction of 
MVs larger than 0.5 μm as a measure of results obtained from 
conventional flow cytometers with MVs below the 0.5 μm limit. 
We did not observe any effect of the oxLDL stimulations on MV 
release, CD36+ MV release, antigen density, as evident by MFI 
values, or on the fraction of small- and large-size MVs. The frac-
tion of small- and large-size MVs varies considerably between 
the individuals.
The activation of platelets plays a critical role in thrombosis. 
Platelet activation involves exposure of phosphatidylserine (PS) 
and subsequent MV release as reviewed in Ref. (14). Furthermore, 
the present results indicate that the density of both PS and cellular 
markers in MVs is increased upon platelet activation. PS is an 
important player in the coagulation cascade taking part in the 
assembly of coagulation complexes at the membrane surface, and 
their presence markedly accelerates the coagulation reaction (15). 
CD41 is located on the platelet surface. It is a receptor of fibrino-
gen involved in platelet aggregation, and upon platelet activation, 
additional complexes of CD41 are translocated to the membrane 
surface (16). Likewise, CD36 is upregulated at the platelet surface 
once the platelet is activated (17, 18). Oxidative stress is a central 
feature of atherothrombotic disease. Our study aimed to focus 
on the involvement of CD36 in the process of platelet stimulation 
and MV release induced by oxLDL. Surprisingly, in our set-up, 
oxLDL did not induce MV release. Other researchers have 
observed increased PMV release of 10–20% when adding similar 
oxLDL concentrations (19), as well as increased aggregation and 
an upregulated expression of P-selectin (19–21). The increased 
MV release was, however, based on incubation of washed 
platelets in buffer, and furthermore, MVs were quantified as total 
MFI in the MV gate as well as by absorbance of MV in an in-
house ELISA Annexin V and CD41 antibodies. It could be argued 
that both these measures are indications of antigen density and 
not of MV number as presented in our study. Furthermore, the 
flow cytometric analyses were performed by a less sensitive flow 
cytometer, and the gating was set to exclude platelets at the upper 
border and with no indication of size. This gating strategy may 
include measurement of apoptotic bodies derived from platelets, 
whereas smaller MVs may not be detected. Thus, despite the pre-
viously demonstrated activation of platelets by oxLDL, there is no 
convincing evidence of MV release induced by oxLDL interaction 
with CD36 on platelets.
In Wang et al. (19), flow cytometry was performed by a FACS 
Calibur, which has a detection limit of around 0.5  μm using 
polystyrene beads as size calibrators (12). It is evident that the 
precise numbers of MVs are not comparable using less sensitive 
and more dedicated flow cytometers, but it is unknown whether 
the number of MVs larger than 0.5 μm correlates with total MV 
number.
By using the size-calibrated fluorescent beads with sizes of 0.2, 
0.5, and 0.9 μm, we were able to establish a gate separating small-
size from large-size MVs defined as below and above 0.5 μm, 
respectively. We observed a large interindividual difference in the 
fraction of small- and large-size MVs, in particular when com-
pared to the variation seen within an individual during oxLDL 
and nLDL incubations. Given the fact that the study population 
was comprised of healthy individuals, this difference could be 
much larger when investigating patients (22). Our results indicate 
possible complications when comparing MV flow cytometric data 
analyzed on conventional flow cytometers which are not able to 
detect MVs below 0.5 μm to data analyzed on the more dedicated 
flow cytometers and stress the importance of standardization of 
flow cytometry MV quantification protocols.
FigUre 4 | Detection of PMVs. (a) PMVs in the small-size gate, (B) the large-size gate, and (c) the total MV gate. (D) Isotype control showing no unspecific 
binding.
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One important preanalytical issue when quantifying plasma 
MVs derived from blood cells, in particular MVs from platelets, 
is the possible release of MVs during sampling and processing 
caused by a fall in temperature. We found a six to eightfold increase 
in two phenotypes of PMVs, in line with other investigators (23, 
24). Whereas this finding stresses the importance of being careful 
when processing blood samples for PMV analyses, the fact that 
the total MV count was unaffected by this indicates that MVs may 
be studied on plasma where lesser care has been taken regarding 
temperature issues and centrifugation procedures during blood 
sample processing.
The strengths of our study include the assumption that we do 
not have any swarm detection when using this method and instru-
ment, as previously described by our group (12). As for weak-
nesses of our study, the experimental set-up at RT may potentially 
influence platelet responsiveness to oxLDL. Future studies should 
include a positive control of platelet activation whose effect is 
documented by MV release. Furthermore, the oxLDL concentra-
tion interval may have been too narrow although it was chosen 
to be in the supraphysiological range and similar to that used in 
studies reporting on oxLDL-induced platelet activation (19–21).
cOnclUsiOn
Incubation with oxLDL had no effect on release of MVs, and 
neither on the fraction between small- and large-size MVs. 
The CD41+ and CD41+CD36+ MV counts were increased in 
PRP when left for 30 min at RT, whereas total MV counts were 
unaffected. Furthermore, MFI values of lactadherin binding, 
CD41, and CD36, which were all increased on the surfaces 
FigUre 5 | Box plot of the fraction of small- and large-size MVs. The 
relative contribution of small MVs (less than 0.5 μm in diameter) is presented 
as the fraction of small vs. large MVs. A fraction of one represents an equal 
number of small and large MVs. The fraction of small- vs. large-size MVs 
during each of the incubation conditions with nLDL and oxLDL are presented 
as box plots for each study participant. Boxes represent twenty-fifth to 
seventy-fifth quartile and median. Whiskers are maximum and minimum 
values. Circles represent outliers.
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of MVs from PRP, indicate a higher activity of platelets at RT. 
These findings address the importance of careful handling when 
investigating PMVs, but it might be possible to study total MV 
count when standard preanalytical procedures are not fully met. 
We found a large interindividual variation in the fraction of 
small- and large-size MVs, which is important to have in mind 
when comparing flow cytometry results analyzed on different 
flow cytometers.
We propose that the procoagulant activity and activation of 
platelets induced by interaction of platelet CD36 with oxLDL 
reported by others may not involve release of MVs. This proposal 
must, however, be confirmed in future studies. Furthermore, 
our results demonstrate great interindividual variability in size 
distribution of PMVs and thereby stress the importance for 
generation of standardized protocols for MV quantification by 
flow cytometry.
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